BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12685842)

  • 1. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
    Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
    Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
    Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo activity of thalidomide in childhood acute leukemia.
    Styczynski J; Czyzewski K; Wysocki M
    Leuk Lymphoma; 2006 Jun; 47(6):1123-8. PubMed ID: 16840205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: preliminary report.
    Styczyński J; Wysocki M; Debski R; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
    Acta Biochim Pol; 2002; 49(1):93-8. PubMed ID: 12136961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
    Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
    Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
    Styczynski J; Wysocki M; Dluzniewska A; Juraszewska E; Balwierz W; Czyzewski K; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Stanczak E; Malinowska I; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Kapuscinska L; Szczepanek J; Kolodziej B; Rafinska B; Kubicka M
    Anticancer Res; 2008; 28(3B):1927-31. PubMed ID: 18630483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual tumor response testing in multiple relapsed acute myeloid leukemia in children.
    Styczynski J; Piatkowska M; Czyzewski K; Pogorzala M; Wysocki M
    Anticancer Res; 2013 Mar; 33(3):1189-93. PubMed ID: 23482801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ
    Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
    Aleskog A; Larsson R; Höglund M; Kristensen J; Nygren P; Lindhagen E
    Anticancer Drugs; 2005 Mar; 16(3):277-83. PubMed ID: 15711179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of glufosfamide in childhood acute leukemia.
    Styczynski J; Wysocki M; Kurylak A; Juraszewska E; Malinowska I; Stanczak E; Płoszynska A; Stefaniak J; Mazur B; Szczepanski T; Ras M
    Anticancer Res; 2002; 22(1A):247-50. PubMed ID: 12017297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
    Jun KR; Jang S; Chi HS; Lee KH; Lee JH; Choi SJ; Seo JJ; Moon HN; Im HJ; Park CJ
    Korean J Lab Med; 2007 Apr; 27(2):89-95. PubMed ID: 18094557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia.
    Styczyński J; Wysocki M; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk A; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
    Neoplasma; 2002; 49(3):178-83. PubMed ID: 12098004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
    Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
    Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia.
    Savaşan S; Buck S; Ozdemir O; Hamre M; Asselin B; Pullen J; Ravindranath Y
    Leuk Lymphoma; 2005 Jun; 46(6):833-40. PubMed ID: 16019527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.